METASTATIC COLORECTAL CANCER MCRC WITH WILD-TYPE RAS: THE CONTINUATION OF ANTI-EGFR THERAPY WITH A CHANGE OF CHEMOTHERAPY AFTER DISEASE PROGRESSION
PDF (Русский)

Keywords

METASTATIC COLORECTAL CANCER (MCRC)
БЛОКАТОРЫ EGFR
ПРОДОЛЖЕННАЯ АНТИ- EGFR ТЕРАПИЯ
CONTINUED ANTI-EGFR THERAPY
ANTI-EGFR DRUGS

How to Cite

Kit, O., Vladimirova, L., Abramova, N., Storozhakova, A., Popova, I., & Tikhanovskaya, N. (2017). METASTATIC COLORECTAL CANCER MCRC WITH WILD-TYPE RAS: THE CONTINUATION OF ANTI-EGFR THERAPY WITH A CHANGE OF CHEMOTHERAPY AFTER DISEASE PROGRESSION. Voprosy Onkologii, 63(3), 456–460. https://doi.org/10.37469/0507-3758-2017-63-3-456-460

Abstract

The effeciency and safety of continuing of EGFR-inhibition while switching the chemotherapy (CT) for patients with RAS wild-type metastatic colorectal cancer (mCRC) were analyzed. 20 patients were recruited. The therapy included: the 1st-line with FOLFOX-6+Cetuximab until progression, then FOLFIRI+ Cetuximab as the 2nd-line therapy. Response rate (RR), toxicity, PFS and OS were evaluated. The control group (20 patients) with 1st-line with FOLFOX-6+anti-EGFR drugand changing of chemotherapy on irinotecan-containing regimen with Bevaci-zumab after progression was used for the comparison of RR, PFS, and OS. OS in patients of study group was higher than in historical control: 29.0±3.4vs22.0±3.1 months, р=0.0458. Continued therapy anti-EGFR drugs in mCRC with wild-type RAS while switching chemotherapy deserves futher evaluation in additional studies in EGFR-dependent mCRC pts.
https://doi.org/10.37469/0507-3758-2017-63-3-456-460
PDF (Русский)

References

Архипова О.Е., Черногубова Е.А., Лихтанская Н.В. и др. Анализ встречаемости онкологических заболеваний в Ростовской области//Пространственно-временная статистика Фундаментальные исследования. -2013. -№ 7-3. -С. 504-510.

Водолажский Д.И., Антонец А.В., Двадненко К.В. и др. Связь мутаций гена KRAS с клинико-патологическими особенностями колоректального рака у пациентов юга России//Международный журнал экспериментального образования. -2014. -№ 1-1. -С. 65-68.

Кит О.И. Проблема колоректального рака в начале XXI века: достижения и перспективы Российский журнал гастроэнтерологии, гепатологии, колопроктологии. -2013. -Т. 23. -№ 3. -С. 65-71.

Кит О.И., Л.Ю. Владимирова, Н.А. Абрамова и др. Опыт применения моноклональных антител -блокато-ров EGFR в лечении метастатического колоректального рака//Фарматека. -2015. -№ 18 (311). -С. 24-28.

Allegra C.J., Jessup J.M., Somerfield M.R. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy//J. Clin. Oncol. -2009. -Vol. 27. -№ 12. -P. 2091-2096.

Cascinu S., Rosati G., Nasti G. et al. A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab//Eur. J. of Cancer. -2015. -Vol.51. -sup. S3 S329 (Abstr. Book ECCO-ESMO 2015.

Ciardiello F., Normanno N., Martinelli E. et al. Cetuximab beyond progression in RAS wild type (WT) metastatic colorectal cancer (mCRC): the CAPRI-GOIM randomized phase II study of FOLFOX versus FOLFOX plus cetuximab//Ann. Oncol. -2015. -Vol. 26 (suppl 4). -P. iv120-iv121.

Jemal A. Global cancer statistics//CA Cancer J. Clin. -2011. -Vol. 2. -№ 61. -Р. 69-90.

Nordlinger B., Van Cutsem E., Gruenberger T et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel//Ann. Oncol. -2009. -Vol. 20. -№ 6. -P. 985-992.

Stintzing S., Jung A., Rossius L. et al: Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients._European Cancer Congress, 2013. -Abstract 17.

Van Cutsem E., Humblet Y, Gruenberger T et al. Cetuximab dose-escalation study in patients with nCRC with no or slight skin reaction on cetuximab standard dose treatment (EVEREST): preliminary PK and efficacy date of a randomized study//Proc. of ASCO, 2007. -Abstract 237.

Van Cutsem E., Peeters M., Siena S. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer//J. Clin. Oncol. -2007. -Vol. 25. -P. 1658-1664.

Vladimirova L., AbramovaN., Kit O. Treatment for RAS wild-type (wt) metastatic colorectal cancer (mCRC): Continuation of anti-EGFR therapy while switching chemotherapy regimen. 2016 Gastrointestinal Cancers Symposium (ASCO). -San Francisco, California, USA, 2016. -Abstract N 744.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2017